Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...

At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 12/31/2024 reporting period, and noticed that Novo-Nordisk AS (Symbol: NVO) was held by 9 of these ...

San Diego, California--(Newsfile Corp. - January 30, 2025) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Novo Nordisk A/S (NYSE: NVO) securities between November 2 ...

ClearBridge Investments stated the following regarding Novo Nordisk A/S (NYSE:NVO) in its Q4 2024 investor letter: “Similarly, we used a temporary price dislocation caused by disappointing ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...

Denmark’s Novo Nordisk (NOV: N) saw its shares rise as much as 13% to ... data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin ...

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license agreement with Novo Nordisk (NOV ... Receive The Pharma Letter daily news bulletin ...

On Tuesday, BofA Securities expressed continued confidence in Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), maintaining a Buy rating and a price target of DKK1,075.00. The endorsement comes amidst ...